{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:58:57Z","timestamp":1764053937979},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,31]]},"DOI":"10.7759\/cureus.65816","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T08:34:58Z","timestamp":1722414898000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Fibroblast Growth Factor Receptor 3 (FGFR3) and Tumor Protein P53 (TP53) as Independent Prognostic Biomarkers in High-Grade Non-muscle Invasive Bladder Cancer"],"prefix":"10.7759","author":[{"given":"Anil","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek K","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwajeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul K","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashustosh","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh K","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey PA","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016, 70:106-19. 10.1016\/j.eururo.2016.02.028","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1210","article-title":"Non-muscle invasive bladder cancer: a review of the current trend in Africa","volume":"10","author":"Cassell A","year":"2019","unstructured":"Cassell A, Yunusa B, Jalloh M, et al.. Non-muscle invasive bladder cancer: a review of the current trend in Africa. World J Oncol. 2019, 10:123-31. 10.14740\/wjon1210","journal-title":"World J Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0551-RA","article-title":"Updates in histologic grading of urologic neoplasms","volume":"144","author":"Rice-Stitt T","year":"2020","unstructured":"Rice-Stitt T, Valencia-Guerrero A, Cornejo KM, Wu CL. Updates in histologic grading of urologic neoplasms. Arch Pathol Lab Med. 2020, 144:335-43. 10.5858\/arpa.2019-0551-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081839","article-title":"Discovery of molecular DNA methylation-based biomarkers through genome-wide analysis of response patterns to BCG for bladder cancer","volume":"9","author":"Ilijazi D","year":"2020","unstructured":"Ilijazi D, Pulverer W, Ertl IE, et al.. Discovery of molecular DNA methylation-based biomarkers through genome-wide analysis of response patterns to BCG for bladder cancer. Cells. 2020, 9:1839. 10.3390\/cells9081839","journal-title":"Cells"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061210","article-title":"Association of smoking, alcohol use, and betel quid chewing with epigenetic aberrations in cancers","volume":"18","author":"Wang TH","year":"2017","unstructured":"Wang TH, Hsia SM, Shih YH, Shieh TM. Association of smoking, alcohol use, and betel quid chewing with epigenetic aberrations in cancers. Int J Mol Sci. 2017, 18:1210. 10.3390\/ijms18061210","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nature09230","article-title":"Epigenetics as a unifying principle in the aetiology of complex traits and diseases","volume":"465","author":"Petronis A","year":"2010","unstructured":"Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature. 2010, 465:721-7. 10.1038\/nature09230","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2508-9","article-title":"TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation","volume":"474","author":"Yatagai N","year":"2019","unstructured":"Yatagai N, Saito T, Akazawa Y, et al.. TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation. Virchows Arch. 2019, 474:315-24. 10.1007\/s00428-018-2508-9","journal-title":"Virchows Arch"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.05.41","article-title":"Epigenetic regulation in bladder cancer: development of new prognostic targets and therapeutic implications","volume":"6","author":"Lee KH","year":"2017","unstructured":"Lee KH, Song CG. Epigenetic regulation in bladder cancer: development of new prognostic targets and therapeutic implications. Transl Cancer Res. 2017, 6:677-68. 10.21037\/tcr.2017.05.41","journal-title":"Transl Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nature14192","article-title":"Function and information content of DNA methylation","volume":"517","author":"Sch\u00fcbeler D","year":"2015","unstructured":"Sch\u00fcbeler D. Function and information content of DNA methylation. Nature. 2015, 517:321-6. 10.1038\/nature14192","journal-title":"Nature"},{"key":"ref11","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder","volume":"63","author":"Bakkar AA","year":"2003","unstructured":"Bakkar AA, Wallerand H, Radvanyi F, et al.. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003, 63:8108-12.","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.30699\/IJP.14.2.148","article-title":"Role of FGFR3 in urothelial carcinoma","volume":"14","author":"Akanksha M","year":"2019","unstructured":"Akanksha M, Sandhya S. Role of FGFR3 in urothelial carcinoma. Iran J Pathol. 2019, 14:148-55. 10.30699\/IJP.14.2.148","journal-title":"Iran J Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2010.05.003","article-title":"FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population","volume":"34","author":"Bodoor K","year":"2010","unstructured":"Bodoor K, Ghabkari A, Jaradat Z, et al.. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 2010, 34:724-32. 10.1016\/j.canep.2010.05.003","journal-title":"Cancer Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang H","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023, 8:92. 10.1038\/s41392-023-01347-1","journal-title":"Signal Transduct Target Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-230x(08)60785-x","article-title":"p53 and human cancer: the first ten thousand mutations","volume":"77","author":"Hainaut P","year":"2000","unstructured":"Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000, 77:81-137. 10.1016\/s0065-230x(08)60785-x","journal-title":"Adv Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/path.2637","article-title":"Massively regulated genes: the example of TP53","volume":"220","author":"Hollstein M","year":"2010","unstructured":"Hollstein M, Hainaut P. Massively regulated genes: the example of TP53. J Pathol. 2010, 220:164-73. 10.1002\/path.2637","journal-title":"J Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/biom9040148","article-title":"Promoter hypermethylation of tumor-suppressor genes p16(INK4a), RASSF1A, TIMP3, and PCQAP\/MED15 in salivary DNA as a quadruple biomarker panel for early detection of oral and oropharyngeal cancers","volume":"9","author":"Liyanage C","year":"2019","unstructured":"Liyanage C, Wathupola A, Muraleetharan S, Perera K, Punyadeera C, Udagama P. Promoter hypermethylation of tumor-suppressor genes p16(INK4a), RASSF1A, TIMP3, and PCQAP\/MED15 in salivary DNA as a quadruple biomarker panel for early detection of oral and oropharyngeal cancers. Biomolecules. 2019, 9:148. 10.3390\/biom9040148","journal-title":"Biomolecules"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317694573","article-title":"Aberrant gene-specific DNA methylation signature analysis in cervical cancer","volume":"39","author":"Bhat S","year":"2017","unstructured":"Bhat S, Kabekkodu SP, Varghese VK, et al.. Aberrant gene-specific DNA methylation signature analysis in cervical cancer. Tumour Biol. 2017, 39:1010428317694573. 10.1177\/1010428317694573","journal-title":"Tumour Biol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S158259","article-title":"Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer","volume":"11","author":"Bayramov B","year":"2018","unstructured":"Bayramov B, Gunes S, Buyukalpelli R, Ayd\u0131n O, Henkel R. Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer. Onco Targets Ther. 2018, 11:4189-96. 10.2147\/OTT.S158259","journal-title":"Onco Targets Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12719","article-title":"A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer","volume":"125","author":"L\u00f3pez JI","year":"2017","unstructured":"L\u00f3pez JI, Angulo JC, Mart\u00edn A, S\u00e1nchez-Chapado M, Gonz\u00e1lez-Corpas A, Col\u00e1s B, Ropero S. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer. APMIS. 2017, 125:787-96. 10.1111\/apm.12719","journal-title":"APMIS"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1726685","article-title":"Aberrant DNA methylation in bladder cancer among Saudi Arabia population","volume":"11","author":"Siddiqui SA","year":"2021","unstructured":"Siddiqui SA, Alshehri FA, Yaqinuddin A. Aberrant DNA methylation in bladder cancer among Saudi Arabia population. J Health Allied Sci NU. 2021, 11:164-9. 10.1055\/s-0041-1726685","journal-title":"J Health Allied Sci NU"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.09.008","article-title":"The FGFR3 mutation is related to favorable pT1 bladder cancer","volume":"187","author":"van Rhijn BW","year":"2012","unstructured":"van Rhijn BW, van der Kwast TH, Liu L, et al.. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012, 187:310-4. 10.1016\/j.juro.2011.09.008","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-200373","article-title":"FGFR3 - a central player in bladder cancer pathogenesis?","volume":"6","author":"Knowles MA","year":"2020","unstructured":"Knowles MA. FGFR3 - a central player in bladder cancer pathogenesis?. Bladder Cancer. 2020, 6:403-23. 10.3233\/BLC-200373","journal-title":"Bladder Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3038","article-title":"Bladder cancers arise from distinct urothelial sub-populations","volume":"16","author":"Van Batavia J","year":"2014","unstructured":"Van Batavia J, Yamany T, Molotkov A, et al.. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014, 16:982-91. 10.1038\/ncb3038","journal-title":"Nat Cell Biol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.07.102","article-title":"Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition","volume":"191","author":"Lamm D","year":"2014","unstructured":"Lamm D, Persad R, Brausi M, et al.. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol. 2014, 191:20-7. 10.1016\/j.juro.2013.07.102","journal-title":"J Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier S","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L, et al.. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin. Eur Urol. 2016, 69:60-9. 10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.145151","article-title":"Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index","volume":"766","author":"Mishra A","year":"2021","unstructured":"Mishra A, Singh N, Shyam H, et al.. Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index. Gene. 2021, 766:145151. 10.1016\/j.gene.2020.145151","journal-title":"Gene"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.163","article-title":"Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma","volume":"23","author":"Catto JWF","year":"2005","unstructured":"Catto JWF, Azzouzi AR, Rehman I, et al.. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005, 23:2903-10. 10.1200\/JCO.2005.03.163","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson DC","year":"2007","unstructured":"Tomlinson DC, Baldo O, Harnden P, Knowles M. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007, 213:91-8. 10.1002\/path.2207","journal-title":"J Pathol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3691","article-title":"Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer","volume":"10","author":"Poyet C","year":"2015","unstructured":"Poyet C, Hermanns T, Zhong Q, et al.. Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncol Lett. 2015, 10:2753-60. 10.3892\/ol.2015.3691","journal-title":"Oncol Lett"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30743","article-title":"DNA methylation and epigenetic events underlying renal cell carcinomas","volume":"14","author":"Tanvir I","year":"2022","unstructured":"Tanvir I, Hassan A, Albeladi F. DNA methylation and epigenetic events underlying renal cell carcinomas. Cureus. 2022, 14:e30743. 10.7759\/cureus.30743","journal-title":"Cureus"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030615","article-title":"A novel methylation marker NRN1 plus TERT and FGFR3 mutation using urine sediment enables the detection of urothelial bladder carcinoma","volume":"15","author":"Zhang J","year":"2023","unstructured":"Zhang J, Xu R, Lu Q, et al.. A novel methylation marker NRN1 plus TERT and FGFR3 mutation using urine sediment enables the detection of urothelial bladder carcinoma. Cancers (Basel). 2023, 15:615. 10.3390\/cancers15030615","journal-title":"Cancers (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4172\/2329-6917.1000227","article-title":"Aberrant DNA methylation in P1 promoter region of TP53 gene in acute leukemia","volume":"5","author":"Zheng YJ","year":"2017","unstructured":"Zheng YJ, Guo F, Zou Y, Jun W. Aberrant DNA methylation in P1 promoter region of TP53 gene in acute leukemia. J Leuk. 2017, 5:10.4172\/2329-6917.1000227","journal-title":"J Leuk"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2013.2201","article-title":"TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status","volume":"33","author":"Jesionek-Kupnicka D","year":"2014","unstructured":"Jesionek-Kupnicka D, Szybka M, Malachowska B, et al.. TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status. DNA Cell Biol. 2014, 33:217-26. 10.1089\/dna.2013.2201","journal-title":"DNA Cell Biol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S221707","article-title":"Impact of TP53 gene promoter methylation on chronic lymphocytic leukemia pathogenesis and progression","volume":"10","author":"Saeed WH","year":"2019","unstructured":"Saeed WH, Eissa AA, Al-Doski AA. Impact of TP53 gene promoter methylation on chronic lymphocytic leukemia pathogenesis and progression. J Blood Med. 2019, 10:399-404. 10.2147\/JBM.S221707","journal-title":"J Blood Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02994-6","article-title":"The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma","volume":"25","author":"Borowczak J","year":"2023","unstructured":"Borowczak J, Szczerbowski K, Maniewski M, et al.. The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma. Clin Transl Oncol. 2023, 25:830-40. 10.1007\/s12094-022-02994-6","journal-title":"Clin Transl Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.mgene.2017.01.002","article-title":"Assessment of p53 mutations, expression and prognosis in bladder cancer patients from Jordan: identification of novel deletion mutations in the DNA-binding domain","volume":"12","author":"Bodoor K","year":"2017","unstructured":"Bodoor K, Al-Ghabkari A, Matalka I, et al.. Assessment of p53 mutations, expression and prognosis in bladder cancer patients from Jordan: identification of novel deletion mutations in the DNA-binding domain. Meta Gene. 2017, 12:33-42. 10.1016\/j.mgene.2017.01.002","journal-title":"Meta Gene"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S318893","article-title":"The prognostic value of FGFR3 expression in patients with T1 non-muscle invasive bladder cancer","volume":"13","author":"Sikic D","year":"2021","unstructured":"Sikic D, Taubert H, Breyer J, et al.. The prognostic value of FGFR3 expression in patients with T1 non-muscle invasive bladder cancer. Cancer Manag Res. 2021, 13:6567-78. 10.2147\/CMAR.S318893","journal-title":"Cancer Manag Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03240-z","article-title":"Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p\/Smad3 axis","volume":"11","author":"Kang W","year":"2020","unstructured":"Kang W, Wang Q, Dai Y, et al.. Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p\/Smad3 axis. Cell Death Dis. 2020, 11:1038. 10.1038\/s41419-020-03240-z","journal-title":"Cell Death Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/275650-evaluation-of-fibroblast-growth-factor-receptor-3-fgfr3-and-tumor-protein-p53-tp53-as-independent-prognostic-biomarkers-in-high-grade-non-muscle-invasive-bladder-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T08:35:03Z","timestamp":1722414903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/275650-evaluation-of-fibroblast-growth-factor-receptor-3-fgfr3-and-tumor-protein-p53-tp53-as-independent-prognostic-biomarkers-in-high-grade-non-muscle-invasive-bladder-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.65816","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}